NeoDynamics hires National Sales Director for the launch of its NeoNavia® Biopsy System
NeoDynamics AB (Nasdaq First North Growth Market Stockholm: NEOD.ST), a medical device company dedicated to advancing the diagnosis and care of cancer, today announced it hired Brendan Carney as National Sales Director. He will lead commercial strategy and execution, including field sales and managed markets for the company.
Mr. Carney has more than 20 years of experience including Genentech and Pharmacia, leading teams and product launches in oncology, infectious diseases, endocrinology, and medical devices. He has most recently served as Sr. Director, Market Access for Syneos Health where he led cross-functional teams launching novel therapies in Oncology and Women’s Health.
“Brendan brings to NeoDynamics a history of significant and successful experience running commercial teams. He is a proven leader and will be an asset to the executive team in developing a strategy that maximizes the potential of our patented pulse technology. During his career, Brendan has worked closely with several of the people at NeoDynamics, so we know he is the perfect person to build our commercialization team”, said Anna Eriksrud, CEO of NeoDynamics.
Mr. Carney commented, “I am excited to join NeoDymanics at this pivotal time as we introduce this novel technology to patients and clinicians in the US. The US breast biopsy market is expected to reach $830mm by 2025. It is a critical market for our success.”
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail firstname.lastname@example.org
CFO Aaron Wong, phone +46 735 972 011 or e-mail email@example.com
Tim Ryan, US Investor Relations +1 646 342 6199 or e-mail firstname.lastname@example.org
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and will soon launch in the USA. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.